TVG to collaborate on PRRS Immunology Group Grant to Progress Novel PRRS Vaccine
The PRRS Immunology Group at The Pirbright Institute has been awarded an Impact Acceleration Award of £9,000 to progress a novel vaccine for porcine reproductive and respiratory syndrome (PRRS), a major threat to the global pig industry. The grant will support a six-month project led by Dr Rory Fortes de Brito under the mentorship of […]
TVG extends its portfolio of animal vaccine candidates into new disease areas
The Vaccine Group is expanding its repertoire of vaccine candidates as it seeks to maximise the potential of its platform herpesvirus gene delivery system. Following the move into important diseases of commercial livestock in recent years TVG has now begun to explore the opportunities presented by the companion animal sector. The common element to each […]
TVG Lassa fever vaccine makes progress
Most emerging infectious diseases affecting humans in the last century have originated in animal reservoirs and are defined as zoonotic. Lassa fever is a significant zoonotic disease threat to human health in West Africa with an estimated 100,000 to 300,000 cases of disease each year, of which about 5,000 are fatal1. In a recently completed […]
S&P Global Interview: TVG eyes investment to support newly extended vaccine pipeline
TVG’s CEO Jeremy Salt met with S&P Global Animal Health at the recent VetHealth Global forum on Canada’s Prince Edward Island to discuss plans to fund the recently extended vaccine pipeline. Read about the interview below.
TVG Future Biotechnologists interview
TVG’s CEO Jeremy Salt was interviewed recently for the online series ‘Future Biotechnologists’. Read the story here.
VetHealthGlobal – see you there!
Dr Jeremy Salt will be attending the VetHealthGlobal meeting in Prince Edward Island next week. A great opportunity to meet with potential collaborators and investors, alongside insighful industry updates.
TVG CEO discusses completion of recent projects
TVG CEO, Jeremy Salt, discusses the recent successful completion of the Streptococcus suis and transmissible Lassa fever vaccine projects.
TVG successfully completes DARPA-funded transmissible Lassa fever vaccine project
Most emerging infectious diseases affecting humans in the last century originated in animal reservoirs and are defined as zoonotic. Lassa fever is a significant zoonotic disease threat to human health in eight West African countries with between an estimated 100,000 to 300,000 cases of disease each year, of which about 5,000 are fatal1. The reservoir […]
Successful Streptococcus suis vaccine project completion
TVG has completed a successful Anglo-Chinese project backed by the Department of Health and Social Care (DHSC), Innovate UK, and the Chinese Ministry of Science and Technology to develop a cross-protective candidate Streptococcus suis (S suis) vaccine against the most prevalent serotypes 2, 7 and 9. S suis is a major bacterial disease that reduces […]
TVG appoints a new Laboratory Manager
As TVG prepares for future growth a new position of Laboratory Manager has been created and we are delighted to announce that after an extensive recruitment campaign Angela Ward has been appointed to the role and will start work on 12th August. Angela has performed a similar role at the Marine Biology Association in Plymouth […]